---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001531"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:23:49.666696+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical reports 82% sham-adjusted liver fat reduction with GLP-1 implant

## Summary
- Sham-implant adjusted liver fat reduction of 82% in obese mouse model from single administration with twice-yearly dosing.
- Previously reported 20% sham-implant adjusted weight loss, comparable to semaglutide arm.
- Clinical development for NPM-115 program (exenatide implant) in overweight/obese patients on track for Q4 2024 start in Australia.
- LIBERATE-1 first-in-human study expected to start Q4 2024 with data in 2025.

## SEC filing metadata
- accession: 0001753926-24-001531
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001531/0001753926-24-001531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001531/vani-20240904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001531
- JSON: https://secwatch.observer/filing/0001753926-24-001531.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.